Analyst firms · Citigroup · BIO
Citigroup BIO price target and rating history
Bio-Rad Laboratories Inc. (BIO) · Industrials
Citigroup rates Bio-Rad Laboratories Inc. (BIO) Neutral with a $300 price target, as of its latest action on Apr 7, 2026. It has published 4 rating actions on BIO since January 2022, including 1 upgrade and 2 downgrades.
- Current rating
- Neutral
- Price target
- $300
- Median target, all firms
- Too few
- Actions on BIO
- 4
Citigroup price target on BIO
Every Citigroup rating on BIO
- Apr 7, 2026
- Oct 1, 2024
- Apr 3, 2024
- Jan 28, 2022
How other firms rate BIO
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| RBC Capital Markets | Outperform | $320 | May 15, 2026 |
| Citigroup | Neutral | $300 | Apr 7, 2026 |
Questions about Citigroup and BIO
- What is Citigroup's price target for BIO?
- Citigroup's latest stated price target for Bio-Rad Laboratories Inc. (BIO) is $300, from its action on Apr 7, 2026.
- What is Citigroup's rating on BIO?
- Citigroup rates BIO Neutral, a neutral rating, as of Apr 7, 2026.
- When did Citigroup last change its view on BIO?
- On Apr 7, 2026, Citigroup downgrades to Neutral from Buy, price target $300.
More BIO rating histories
All Citigroup ratingsBIO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.